BAT 2024 Results Summary: New Business Earnings Growth,Despite 5.2% Revenue Decline

Apr.18.2025
BAT 2024 Results Summary: New Business Earnings Growth,Despite 5.2% Revenue Decline
Despite a 5.2% drop in reported revenue in 2024, BAT's organic revenue increased 1.3%, with new tobacco business profits.

Key points:

Performance in 2024: Despite a 5.2% decrease in reported revenue, organic revenue increased by 1.3%. The new tobacco business achieved profitability two years ahead of schedule, contributing an additional £2.51 billion in growth.

Progress of new tobacco products: The global number of adult users of new tobacco products has reached 29.1 million, accounting for 17.5% of company revenue.

Progress in harm reduction strategy: Continuing to advance the "Omni™ Declaration" and responsible product development, emphasizing collaboration with regulatory agencies.

Projected for 2025: Focus on execution and deployment, with expected annual revenue growth of 1% and profit growth of 1.5-2.5%; the second half of the year will be the main driver of growth.

Sustainable Development Goals: Reduce harm, climate, nature, recycling, community.

Board Changes: Soraya Benchikh appointed as Chief Financial Officer, Uta Kemmerich-Keil appointed as Independent Director.


On April 16, British American Tobacco (BAT) held its annual shareholders' meeting for the year 2025, where the BAT chairman provided a systematic summary of the company's operating results in 2024 and outlook for 2025, reaffirming their strategic direction towards a "smoke-free world." In 2024, which was a year for investment deployment, the group's financial performance met initial expectations. 

 

With reported exchange rates, the group's total revenue decreased by 5.2% year-on-year; however, it grew by 1.3% on a constant currency and organic basis. Adjusted organic operating profit increased by 1.4%, with a cash conversion rate of 101%. In particular, the new category tobacco business achieved adjusted growth of £251 million at constant exchange rates, with a category profit margin of 7.1%.

 

BAT stated that the overall performance showed the business resilience and employee execution ability. The new tobacco business achieved profitability two years ahead of schedule, marking a key milestone in the transformation process.

 

 

Become a primarily smoke-free enterprise by 2035, and to promote the establishment of industry standards

 

 

In 2023, BAT announced that it has refined its strategy, continuing to focus on the core vision of "building a smoke-free world" and aiming to achieve a revenue structure primarily focused on smoke-free business by 2035. The current number of users of new tobacco products is 29.1 million, accounting for 17.5% of the group's total revenue.

 

BAT emphasizes that driving transformation relies on precise execution, continuous product innovation, and responsibly meeting the preferences of adult consumers.

 

British American Tobacco (BAT) has stated that the promotion of new tobacco products should be based on harm reduction principles, and has pointed out that New Zealand and Sweden have already achieved or are close to achieving their "smoke-free" national goals. This demonstrates the positive results brought about by regulatory policies supporting harm reduction strategies.

 

According to BAT's warning, restrictive policies implemented by some countries may have unintended consequences, hindering adult smokers from transitioning to lower-risk alternative products. BAT is calling for enhanced policy dialogue based on scientific evidence, and has outlined five industry development goals through its regulatory position statement on e-cigarette products and the forthcoming release of "Omni™" (set to launch in London in September 2024 and internationally in 2025).

 

To prevent minors from accessing, including age verification through technological means; promote responsible packaging, marketing, and flavor use; strengthen product safety assessments; increase the recyclability of equipment, such as removable batteries; support effective market supervision and penalties for violations. BAT said it will continue to seek multi-party collaboration with policymakers, regulatory agencies, and public health organizations to promote the establishment of sustainable industry standards.

 

 

Deployment priorities and financial expectations for the year 2025

 

 

The year 2025 has been dubbed as the "year of deployment," as BAT plans to restore profit growth in the US market and continue to roll out product innovations. Full-year revenue is expected to increase by approximately 1%, with adjusted operating profit growth of 1.5%-2.5% (including a 1.5% headwind from foreign exchange trading). The second half of the year is expected to be the main driver of growth.

 

The exchange rate factor is expected to have a transformative impact of 2% on annual operating profit. BAT maintains its medium-term goal: from 2026 onwards, it aims to achieve annual revenue growth of 3%-5% and operating profit growth of 4%-6%.

 

In terms of cash flow, BAT expects to generate over £50 billion in free cash flow between 2024 and 2030, maintaining capital allocation discipline, including:

 

Continue investing in transformation; balance deleveraging, dividend growth, and share buybacks; selectively pursue small-scale mergers and acquisitions to accelerate the transformation process. BAT has announced a 2% increase in dividends by 2025 and will implement a £9 billion share buyback.

 

Since the last shareholders' meeting, there have been changes to the board of directors. Soraya Benchikh was appointed as Chief Financial Officer and Director in May 2024, while in February 2025, Uta Kemmerich-Keil joined the board as an independent non-executive director and also joined the audit and nomination committee. Murray Kessler became a non-executive director in November 2024 but stepped down in February 2025 to focus on his recent appointment as CEO of Wellington International LLC.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Philip Morris Japan (PMJ) launched TEREA Black Mint Pearl on October 15, 2026, introducing the first capsule-equipped heated tobacco stick in the TEREA Black range for IQOS ILUMA devices. The product combines a strong menthol profile with a crushable mint capsule and is priced at ¥640 per 20-stick pack, including tax. Sales began at four IQOS stores and selected retail partners on October 15, with distribution expanding to convenience stores and other tobacco retailers nationwide from October 19. The launch brings Japan's TEREA portfolio to 28 variants, including 21 menthol-related products, or 75% of the range.
product
Oct.16 by 2Firsts Perspectives
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23